4KV5

scFv GC1009 in complex with TGF-beta1.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3 Å
  • R-Value Free: 0.300 
  • R-Value Work: 0.229 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Structures of a pan-specific antagonist antibody complexed to different isoforms of TGF beta reveal structural plasticity of antibody-antigen interactions.

Moulin, A.Mathieu, M.Lawrence, C.Bigelow, R.Levine, M.Hamel, C.Marquette, J.P.Le Parc, J.Loux, C.Ferrari, P.Capdevila, C.Dumas, J.Dumas, B.Rak, A.Bird, J.Qiu, H.Pan, C.Q.Edmunds, T.Wei, R.R.

(2014) Protein Sci. 23: 1698-1707

  • DOI: 10.1002/pro.2548
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Various important biological pathways are modulated by TGFβ isoforms; as such they are potential targets for therapeutic intervention. Fresolimumab, also known as GC1008, is a pan-TGFβ neutralizing antibody that has been tested clinically for several ...

    Various important biological pathways are modulated by TGFβ isoforms; as such they are potential targets for therapeutic intervention. Fresolimumab, also known as GC1008, is a pan-TGFβ neutralizing antibody that has been tested clinically for several indications including an ongoing trial for focal segmental glomerulosclerosis. The structure of the antigen-binding fragment of fresolimumab (GC1008 Fab) in complex with TGFβ3 has been reported previously, but the structural capacity of fresolimumab to accommodate tight interactions with TGFβ1 and TGFβ2 was insufficiently understood. We report the crystal structure of the single-chain variable fragment of fresolimumab (GC1008 scFv) in complex with target TGFβ1 to a resolution of 3.00 Å and the crystal structure of GC1008 Fab in complex with TGFβ2 to 2.83 Å. The structures provide further insight into the details of TGFβ recognition by fresolimumab, give a clear indication of the determinants of fresolimumab pan-specificity and provide potential starting points for the development of isoform-specific antibodies using a fresolimumab scaffold.


    Organizational Affiliation

    Sanofi Biotherapeutics, Framingham, Massachusetts, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Transforming growth factor beta-1
C, D, A, B
112Homo sapiensMutation(s): 0 
Gene Names: TGFB1 (TGFB)
Find proteins for P01137 (Homo sapiens)
Go to Gene View: TGFB1
Go to UniProtKB:  P01137
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
heavy chain GC1009 scFv
J, H, E, G
136N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
light chain GC1009 scFv
I, L, F, K
116N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3 Å
  • R-Value Free: 0.300 
  • R-Value Work: 0.229 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 108.188α = 90.00
b = 171.769β = 111.30
c = 109.876γ = 90.00
Software Package:
Software NamePurpose
CrystalCleardata reduction
PHENIXrefinement
PDB_EXTRACTdata extraction
CrystalCleardata scaling
CrystalCleardata collection
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-09-24
    Type: Initial release
  • Version 1.1: 2014-12-03
    Type: Database references